Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Profile Name||FGFR2 - USP33|
|Gene Variant Detail|
|Relevant Treatment Approaches|
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|FGFR2 - USP33||cholangiocarcinoma||predicted - sensitive||Pemigatinib||Case Reports/Case Series||Actionable||In a Phase I trial (FIGHT-101), Pemazyre (pemigatinib) treatment in a cholangiocarcinoma patient harboring FGFR2-USP33 led to a partial response that was maintained for 10.7 months, followed by disease progression, however, patient continued on Pemazyre (pemigatinib) treatment for over 12 months further, due to lack of alternative treatment options (PMID: 35176457; NCT02393248).||35176457|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|